Sweden· SE-20160309000010
Suliqua 100 enheter/ml+33 mikrogram/ml Injektionsvätska, lösning i förfylld injektionspenna
A medicinal product containing insulin glargine + lixisenatide, registered in Sweden by Sanofi Winthrop Industrie.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Insulin Glargine + Lixisenatide
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20160309000010
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin glargine + lixisenatide in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSULIQUASanofi Winthrop Industrie, Gentilly
- PolandSuliquaSanofi Winthrop Industrie
- SpainSULIQUA 100 UNIDADES/ML + 33 MICROGRAMOS/ML SOLUCION INYECTABLE EN PLUMA PRECARGADASanofi Winthrop Industrie
- FinlandSuliquaSanofi Winthrop Industrie
- United KingdomSuliqua 100units/ml / 33micrograms/ml solution for injection 3ml pre-filled SoloStar pensSanofi
- IrelandSuliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled penSanofi-Aventis Groupe
- SwitzerlandSuliqua 100/33, solution injectableSanofi-Aventis (Suisse) SA
- IcelandSuliquaSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Suliqua
- Liechtenstein · Suliqua
- Norway · Suliqua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/98568699-7bea-49b2-8650-7d410ee0f2ea GET /v1/drugs/98568699-7bea-49b2-8650-7d410ee0f2ea?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EPAR",
"EMA"
],
"se_npl_id": "20160309000010",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20160309000010",
"product_doc_link": "https://www.ema.europa.eu/sv/documents/product-information/suliqua-epar-product-information_sv.pdf"
}See everything about insulin glargine + lixisenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.